Thank you This live web event has ended. Thank you for attending. Contributors Hetty Carraway, MD, MBA Dr. Carraway received her medical degree from the University of Massachusetts, completed internship and residency in the Department of Medicine on the Osler Service at Johns Hopkins Hospital, and completed her Oncology fellowship at Johns Hopkins University School of Medicine. She also obtained her MBA in the Business of Health from the Carey Business School at Johns Hopkins. She is a translational clinical scientist at the Cleveland Clinic, with a research focus on experimental therapeutics of acute leukemia, including using novel biological agents (such as epigenetic agents) for adults with acute leukemia as well as new approaches to the treatment of refractory acute leukemia. David Sallman, MD Dr. David Sallman is an Assistant Member in the Department of Malignant Hematology at Moffitt Cancer Center. Dr. Sallman’s clinical interests are myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and myeloproliferative neoplasms (MPN). Dr. Sallman earned his MD degree from the University of South Florida College of Medicine. He completed an Internal Medicine Residency at Massachusetts General Hospital and, most recently, a Hematology/Oncology Fellowship at Moffitt Cancer Center. His research interests focus on the development of novel, targeted therapeutic strategies (Phase I and II clinical trials) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), based on the underlying mutational drivers of each disease.